Cargando…
A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance
Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but the effectiveness of any regimen is limited and recurrence rates are high. Here, we investigated the molecular mechanisms of acquired resistance in GBC through the development and chara...
Autores principales: | Vergara-Gómez, Luis, Bizama, Carolina, Zhong, Jun, Buchegger, Kurt, Suárez, Felipe, Rosa, Lorena, Ili, Carmen, Weber, Helga, Obreque, Javiera, Espinoza, Karena, Repetto, Gabriela, Roa, Juan C., Leal, Pamela, García, Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139168/ https://www.ncbi.nlm.nih.gov/pubmed/37108401 http://dx.doi.org/10.3390/ijms24087238 |
Ejemplares similares
-
Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer
por: García, Patricia, et al.
Publicado: (2020) -
Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool
por: Obreque, Javiera, et al.
Publicado: (2023) -
AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines
por: Leal, Pamela, et al.
Publicado: (2013) -
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice
por: Weber, Helga, et al.
Publicado: (2015) -
Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line
por: Viscarra, Tamara, et al.
Publicado: (2019)